GT Biopharma Inc is a biotechnology company focused on developing innovative immuno-oncology therapies to treat various forms of cancer. The company specializes in harnessing the power of the immune system to identify and destroy cancer cells through its proprietary platforms, which include novel antibody constructs and immune cell engineering. By advancing its therapeutic candidates through clinical trials, GT Biopharma aims to improve treatment outcomes for patients suffering from solid tumors and hematological malignancies. Through strategic partnerships and cutting-edge research, the company is dedicated to addressing unmet medical needs in the oncology space. Read More
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.
The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.
GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be offered in a registered direct offering priced at-the-market under Nasdaq rules.
GT Biopharma shares are moving on heavy trading volume despite a lack of company-specific news. The stock is one of the top trending tickers on Stocktwits which may point to a rally led by retail traders. According to data from Benzinga Pro, more than 60.4 million shares have been traded in the session, far exceeding the stock's 100-day average of less than 11,000 shares.
